EARLY AND LATE COMPLICATIONS OF PROSTATE LOW DOSE BRACHYTHERAPY

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Is Radical Prostatectomy Adequate For High Risk Prostate Cancer?
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.
US TOO INTERNATIONAL, INC US TOO GREATER QUAD CITIES PROSTATE CANCER SUPPORT GROUP.
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
Radical Prostatectomy Sept 2009 till Aug 2010 South Mersey Cancer Network Manal Kumar Consultant Urologist.
PROSTATE CANCER EXPECTED MANAGEMENT & CURATIVE TREATMENT Dr. Abdullah A. Ghazi (R5) KSMC.
NEW OPTIONS IN PROSTATE CANCER TREATMENT Presented by Triangle Urology Associates, P.A.
Prostate Needle Biopsy: The Pitfalls and the Role of the Pathologist – Patient Track Prostate Cancer Symposium “Intriguing Cases / Emerging Strategies.
Prostate Radiotherapy A-Z
PROSTATE CANCER LETS DEBATE !!!! Dr Fred C Tyler MBChB FRCS FCS UROL.
Everything you need to know about Prostate Radiotherapy During the talk or at end send QUESTIONS: Rob.
PROGRESS IN MANAGEMENT OF PROSTATE CANCER Presented by Dr. J. Nkusi on the October 2007, 38 th Congress of the Botswana Medical Association.
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
© Cancer Research UK 2008 Registered charity number Prostate cancer – UK December 2009.
Akbar Ashrafi Surgical Students Society of Melbourne September 2010.
 These slides were extracted from a larger set of comprising a presentation entitled “Comparing Treatment Results of PROSTATE CANCER” dated 15_01_2013(3).
Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma
Radiotherapy - the art of the invisible Terry Kehoe Consultant Clinical Scientist Head of Oncology Physics Edinburgh Cancer Centre “How to crack a walnut”
Brachytherapy Medical radiation.
Conclusions HDR brachytherapy boost combined with moderate dose external beam irradiation resulted in a very high local control rate and few recurrences.
Prof Stephen Langley Professor of Urology St Luke’s Cancer Centre, Guildford, UK PGMS, University of Surrey Focal Brachytherapy UK experience.
RISK OF NON SIGNIFICANT PROSTATE CANCER IN PROSTATE CANCER PATIENTS DIAGNOSED BY AN EXTENDED PROSTATE NEEDLE BIOPSY PROCEDURE AND TREATED BY RADICAL PROSTATECTOMY.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.
Updated 5-year Biochemical Relapse-Free Survival after Prostate Brachytherapy Jenny P. Nobes St. Luke’s Cancer Centre, The Royal Surrey County Hospital,
Ten Year Outcomes In Men Under 60 Treated With Iodine-125 Permanent Brachytherapy As Monotherapy GU - Prostate Cancer: Novel Imaging (MRI,PET) & Brachytherapy.
Comparison of Toxicity Profiles Associated with Three High-Dose-Rate Brachytherapy Treatment Schedules for Favorable-Risk Prostate Cancer Maha Saada Jawad,
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.
1 Prostate Cancer. 2 Prostate Gland Muscular Walnut-sized gland Makes seminal fluid Muscles contract to push semen through the urethra Located directly.
Understanding Prostate Myths
DANYLO HALYTTSKY LVIV NATIONAL UNIVERSITY (UKRAINE) - 1 UROLOGIC DEPARTMENT OF WROCLAW REGIONAL HOSPITAL (POLAND) - 2 The Term of Expendient Use of Permanent.
David Spellberg, MD Naples Urological Associates High Intensity Focused Ultrasound Sonablate ® HIFU A Minimally Invasive Way to Treat Prostate Cancer.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
HIFU AND CRYOSURGERY David Spellberg M.D., FACS.
Stereotactic Body Radiation Therapy for Early Stage Prostate Cancer: Outcomes from a Single Institution Study Stereotactic Body Radiation Therapy for Early.
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
Debra Freeman, MD – Naples Christopher King, MD, PhD - Stanford.
David Spellberg, M.D., FACS Naples Urology Associates, P.A.
High Intensity Focused Ultrasound Sonablate® HIFU
Carcinoma of the prostate. INTRODUCTION Prostate cancer is the most common cancer diagnosed and is the second leading cause of cancer death in men in.
Stereotactic Body Radiation Therapy: An Emerging Treatment Approach for Early Stage Prostate Cancer Stereotactic Body Radiation Therapy: An Emerging Treatment.
Conflicts of Interest Nil conflicts of interest..
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital.
Journal Club August 10, 2012 Ryan M. Zitnay MD. Case 71 y/o male veteran w PMH CAD s/p MI, HTN, HL, constipation Followed by urology for rising PSA x.
Dose Calculations for Cyberknife Stereotactic Body Radiation Therapy For CK, one can fractionate the therapy yet remain convenient and non-invasive for.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized and Advanced Prostate Cancer David M. Spellberg M.D., FACS Naples.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized Prostate Cancer David M. Spellberg M.D., FACS.
Brachytherapy in Carcinoma Prostate
Carcinoma of Prostate Issam S. Al-Azzawi, MD,FICMS,FEBU By
Carcinoma of the prostate
Radiation therapy for Early Stage Prostate Cancer
Bladder Cancer and Prostatic Cancer
Is Brachytherapy 125I still needed in Prostate cancer treatment?
MINIMALLY INVASIVE URO-ONCOLOGICAL TREATMENTS ON THE AMBULATORY SETTING PROSTATE BRACHYTHERAPY I125 Luís Campos Pinheiro.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
Laparoscopic Radical prostatectomy: Is it still a treament of choice?
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized and Advanced Prostate Cancer David M. Spellberg M.D., FACS Naples.
Prostate Cancer: Highlights from 2006
ROBOTIC ASSISSTED RADICAL PROSTATECTOMY OUR INITIAL EXPERIENCE
Apollo Gleneagles Hospitals,
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 62, Issue 1, Pages (July 2012)
Current Guidelines in the treatment of Prostate Cancer: what is most appropriate for Nigerian patients? Dr Emmanuel Ajibola Jeje BSc. M. B. Ch.B; FMCS;
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Active Surveillance for Low Risk Prostate Cancer
Presentation transcript:

EARLY AND LATE COMPLICATIONS OF PROSTATE LOW DOSE BRACHYTHERAPY DZNELADZE, MD, PhD G. BOTCHORISHVILI, MD, PROF. A. BOCHORISHVILI, MD

Prostate Brachytherapy accounts more than one century Prostate Brachytherapy accounts more than one century. First attempt to treat prostate cancer with radiation was done in 1901 in Paris, France.

Different techniques and different radioactive materials had been used to treat prostate cancer

Results were controversial until 80th, when ultrasound developed and industry offered transrectal approach and commercially available I125 and P103 seeds.

One of the first patients treated by modern Prostate Brachytherapy – Low Dose Radiation

LDR - the method we use to treat patients with prostate cancer since 2010

Awareness among patients and even among urologists was and is still poor

Clinical Stage Gleason Score PSA (ng/ml) Low T1-T2a 2-6 <10 National Comprehensive Cancer Network Risk Group Definitions for Clinically Staged Patients Clinical Stage Gleason Score PSA (ng/ml) Low T1-T2a 2-6 <10 Intermediate T2b-T2c 7 10-20 High T3a-T3b 8-10 >20 Very High T4 Node Positive

Different kinds of techniques are proposed to plan and insert radioactive materials into the prostate Pre-treatment planning with previously loaded needles. Real-Time planning with sophisticated software to plan and insert seeds. Peripheral planning & inserting the seeds using Mick Applicator.

Peripheral planning & inserting the seeds using Mick Applicator

Very High T4 Node Positive National Comprehensive Cancer Network Risk Group Definitions for Clinically Staged Patients Clinical Stage Gleason Score PSA (ng/ml) Low T1-T2a 2-6 <10 Intermediate T2b-T2c 7 10-20 High T3a-T3b 8-10 >20 Very High T4 Node Positive

We insert transrectal transducer (ultrasound scanner B&K) to visualize prostate, make Real Time planimetry and control seed placement

We calculate number of seeds, which is necessary to give to the prostate mPD 144Gy

Transperinealy we insert peripheral needles and than implant seeds (using Mick Applicator. Number of seeds implanted peripherally is 75% of that totally prescribed. 25% of seeds we implant internally

Seed implantation is checked by X-ray immediately after the procedure

From 2010-2017 years 51 Patients

Hematuria after LDR. TUC. (e) N Patient # age Initial stage Initial PSA Initial PV Initial GS Vmax After5 years   PV Complication Death 1 68 y T1c 12,1 35cc 3+3 12ml/s 0,21 22cc 11ml/s no 2 62 y T2a 15,1 50cc 3+4 10ml/s 0,32 40cc 3 65 y 12,0 49cc 13ml/s 0,5 38cc 16ml/s 4 54 y 14,9 42cc 0,23 15ml/s 5 78 y 9,5 80cc+adt =50cc 0,65 55cc 6 T2b 19,0 4+3 17ml/s + 10,5 30cc 14ml/s Hematuria after LDR. TUC. (e) 7 74 y 18,1 45cc ++ 0.01 25cc ADT 8 10,0 48cc 0,16 9 71 y 16,5 44cc 0,2 32cc 10 12,5 0,6 36cc 11 70 y 9,6 13,0ml/s 26cc 12 72 y 15,6 9ml/s 0,1 13 76 y 16,0 0,8 Dysuria (e+l) 14 16,1 +++ 9,1 Hormonal Mono Scheduled salvage RP 15 9,8 16 5,6 0,3 17 6,8 Dysuria (e) 18 8,1 39cc 19 66 y 1,0 20 67 y 0.1 21 59 y 5,0 0,01 20cc 22 7,1 34cc 23 8,0 24 17,8 ++++ TURP 25 69 y 10,6 0,9 Proctitis (l) 26 7,6 33cc 27 16,7 +++++ - Cancer related 28 7,2 29 11,0 37cc

29 Patients Average age – 68 Highest PSA - 18.1ng/ml

Histological 18 patients Gs6 3+3 (Grade 1)

Prostate volume 30-50cc Urodynamics Vmax lowest 9,1ml/s

During 5 years PSA control every 3 month TRUS every 6 month

Cancer status for 5 years

4 patients cancer recurancy 3 patient – ADT 1 Patient died due to cancer progression 1 patient is waiting for salvage prostatectomy

Early Complications Two cases of Urine Retention: 1 case retention 1 case with hematuria

Early Complications

Late complications

Conclusion Prostate Low Dose Radiation is well accepted method of treatment of prostate cancer in Low and sometime Intermediate Risk patients. This method is recommended by guidelines of Urology and Radiation Oncology associations. We know, that modern approach to manage low risk patients is also active survilance. Though, many patients diagnosed with prostate cancer are anxious and demand to be treated. Prostate Low Dose Brachytherapy is good option to offer to those patients. This is effective method of treatment with comparably less complications. Number of early and late complications, we observed are limited to urine retention, bleeding and inflammation associated with radiation. Any inflammation lasts until radiation expires. Urine retention and bleeding must be treated surgically. Although surgeon must aware, that intervention after radiation should be minimal. We had no case if urine incontinence after implantation. We know, that this is rare complication and in most of the cases it happens after TURP.

Thank you for your attention.